<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03318523</url>
  </required_header>
  <id_info>
    <org_study_id>228PD201</org_study_id>
    <secondary_id>2016-0044610-95</secondary_id>
    <nct_id>NCT03318523</nct_id>
  </id_info>
  <brief_title>Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease</brief_title>
  <acronym>SPARK</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the dose-related safety of BIIB054, to evaluate the pharmacodynamic effects of
      BIIB054 on the integrity of nigrostriatal dopaminergic nerve terminals, to assess the
      pharmacokinetic (PK) profile of BIIB054 and to evaluate the immunogenicity of BIIB054.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 6, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Event (AEs) and Serious Adverse Event (SAEs)</measure>
    <time_frame>Up to Week 52</time_frame>
    <description>An AE is any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose results in death, requires inpatient hospitalization, results in persistent or significant disability and/or results in a congenital anomaly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Clinical Laboratory Test Data</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Vital Sign Measurements</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Neurological and Physical Examination Findings</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Electrocardiograms (ECGs)</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Brain Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Striatal Binding Ratio (SBR) in Putamen, Striatum, and Caudate as Measured by Striatal-Photon Emission Computed Tomography (SPECT) Imaging of the Dopamine Transporter With Ioflupane I123 (DaTscan™)</measure>
    <time_frame>Baseline, Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of BIIB054 in the Serum</measure>
    <time_frame>Baseline and at multiple time points (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-BIIB054 Antibodies in the Serum</measure>
    <time_frame>Baseline and at multiple time points (up to 2 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">311</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Year 1: Participants will receive matching placebo to BIIB054 on Day 1 and then every 4 weeks.
Year 2: Participants who received placebo in year 1 will be randomized into one of the active treatment arms in year 2 and will receive BIIB054 intravenous (IV) infusion on Week 52 and then every 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIIB054 250 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive BIIB054 250 mg intravenous (IV) infusion on Day 1 and then every 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIIB054 1250 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive BIIB054 1250 mg IV infusion on Day 1 and then every 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIIB054 3500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive BIIB054 3500 mg IV infusion on Day 1 and then every 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered as specified in the treatment arm</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB054</intervention_name>
    <description>Administered as specified in the treatment arm.</description>
    <arm_group_label>BIIB054 250 mg</arm_group_label>
    <arm_group_label>BIIB054 1250 mg</arm_group_label>
    <arm_group_label>BIIB054 3500 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Diagnosed with Parkinson's disease (PD) within a maximum of 3 years prior to
             Screening.

          -  Score of ≤2.5 on the Modified Hoehn and Yahr Scale.

          -  Has not received levodopa or any other treatment for PD (dopamine agonists,
             amantadine, anticholinergics, MAO-B inhibitors, or safinamide) for at least 12 weeks
             prior to Day 1 and, in the opinion of the Investigator, is not expected to require PD
             treatment for at least 6 months following Day 1. Maximum total duration of prior PD
             regimens should not exceed 30 days.

          -  Screening dopamine transporter (DaT)/ single-photon emission computed tomography
             (SPECT) results consistent with neurodegenerative Parkinsonism (central reading).

          -  All women of childbearing potential and all men must practice highly effective
             contraception during the study and for 6 months after their last dose of study
             treatment.

        Exclusion Criteria:

          -  Presence of freezing of gait.

          -  MOCA score &lt;23 or other significant cognitive impairment or clinical dementia that, in
             the opinion of the Investigator, would interfere with study evaluation.

          -  History of or screening brain magnetic resonance imaging (MRI) scan indicative of
             clinically significant abnormality, as read by central reader.

          -  History of severe allergic or anaphylactic reactions, or history of hypersensitivity
             to BIIB054 or any of the inactive ingredients in the drug product or to radioligands
             or iodine used in the study.

          -  Participation in any active immunotherapy study targeting alpha-synuclein.

          -  Use of allowed medications not previously specified at doses that have not been stable
             for at least 8 weeks before Day 1, and/or that are not expected to remain stable for
             the duration of the study.

          -  Clinically significant abnormal laboratory test values at Screening, as determined by
             the Investigator.

          -  Blood donation (1 unit or more) within 8 weeks before Day 1 (must also refrain from
             donating blood for the duration of the study).

        NOTE : Other protocol defined Inclusion/Exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Biogen Medical Information</last_name>
    <phone>866-633-4636</phone>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenna Smith</last_name>
      <phone>205-996-2807</phone>
    </contact>
    <investigator>
      <last_name>Natividad Stover</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hopsital &amp; Medical Center- Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Banner Sun Health Research Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ochsner Health System</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley LaRoche</last_name>
      <phone>504-703-0755</phone>
      <email>ashely_laroche@ochsner.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Erickson</last_name>
      <email>herickson@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Quest Research Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee</last_name>
      <phone>248-957-8940</phone>
      <email>renee@questri.com</email>
    </contact>
    <investigator>
      <last_name>Aaron L Ellenbogen, DO, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Dimos</last_name>
      <phone>336-716-8694</phone>
      <email>jdimos@wakehealth.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.thesparkstudy.com/</url>
    <description>Study Website</description>
  </link>
  <link>
    <url>https://foxtrialfinder.michaeljfox.org/trial/5100/</url>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2017</study_first_submitted>
  <study_first_submitted_qc>October 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2017</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BIIB054</keyword>
  <keyword>Parkinson's Disease</keyword>
  <keyword>Alpha-synuclein</keyword>
  <keyword>Alpha synuclein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

